How much revenue does Harbin Medisan Pharmaceutical make?

Harbin Medisan Pharmaceutical reported 789.42 million CNY in revenue for fiscal year 2025, down 30.3% from 1.13 billion CNY in fiscal year 2024. In Q1 2026 revenue was 228.84 million CNY.

What companies are similar to Harbin Medisan Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SS), Sinotherapeutics Inc. (688247.SS), Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ), Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ).

Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) Stock

About Harbin Medisan Pharmaceutical Co., Ltd.

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folin...

At a glance

Harbin Medisan Pharmaceutical reported revenue of 789.42 million CNY for fiscal year 2025, down 30.3% from fiscal year 2024, and net income of -339.63 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 228.84 million CNY, up 11.6% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.